Compare McDonald's Corp (MCD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Repligen Corporation Common Stock — how do they compare? McDonald's Corp trades at $239.47 (market cap $166.87B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: McDonald's Corp is far larger — about 15× Repligen Corporation Common Stock's market cap, and McDonald's Corp pays a 3.27% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 165 Days and Repligen Corporation Common Stock for 0 Days on average.
| MCD | RGEN | |
|---|---|---|
Market Cap | $166.87B | $11.14B |
Volume | 4,543,119 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $194.57 |
52-Week Low | $230.88 | $102.87 |
Typical Hold Time | 165 Days | 0 Days |
Enterprise Value | $220.64B | $11.02B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $235.65, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 EPS of $3.38, beating expectations, and maintains robust profitability with a 31.72% net income margin. Recent news highlights McDonald's new 'NEXT' growth strategy focusing on automation and menu innovation to win back customers amid competitive pressures.
The stock offers a compelling long-term opportunity with 58.7% analyst buy ratings and a $284.70 consensus price target, representing 21% upside. Key risks include inflationary pressures on franchisee margins and high debt levels. The current valuation at 19.16x P/E appears reasonable given the company's stable cash flows and dividend consistency.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
